Please assess the completion status of the following clinical trial:

Trial Title: Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients treated with the same regimen including 3 HAART from at least 4 months~* Aged 18 years or older~* Who gave informed consent to the participation to the study~* With at least two viral load \< 50 copies/mL in two consecutive determinations at least 6 months apart (tolerance of two weeks)~* With CD4 cell count \> 200 cells/μL and absence of any opportunistic infection or AIDS-related disease for at least one year prior to the screening.~* With R5 tropism by viral DNA genotyping (geno2pheno clonal)~* With CD4 cell count nadir\>50 cell/mmc or 100 cell/mmc if previous enfuvirtide or integrase inhibitors use~Exclusion Criteria:~* With at least one major or two minor mutation conferring resistance to darunavir reported in the update list of International AIDS Society - USA , in previous resistance test~* Previous D/M or X4 viral tropism~* Previous major clinical toxicities (grade \>=3) to the proposed drugs of the study~* Pregnancy or breast feeding, desire of pregnancy in the short term~* Past exposure to Chemokine Receptor 5 antagonist~* HBsAg serostatus~* Liver cirrhosis of class C (Child-Pugh)~* Sulpha drug hypersensitivity~* The presence of major non AIDS-defining diseases that, in the opinion of the investigator, may compromise the retention of the patient in the study for the necessary follow-up period.~* Estimated glomerular filtration \< 30 ml/min (cockroft-Gaut; MDRD formula if black-African or african-american) at screening visit~* Hypertransaminasemia of grade IV (more than 10 times the upper normal limit) at screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MARAVIROC, DARUNAVIR/r (Type: EXPERIMENTAL): Treatment simplification from a standard combined antiretroviral therapy including 3 drugs to Maraviroc plus Darunavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy
- current ART with 3 drugs (Type: SHAM_COMPARATOR): Patients on HAART with three drugs and HIV RNA below 50 copies/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).